NICE makes first immunotherapy combination immediately available in advanced kidney cancer

05:53 EDT 8 Apr 2019 | ecancermedicalscience

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending the combination of nivolumab plus ipilimumab to treat NHS patients in England with an advanced form of the most common type of...

More From BioPortfolio on "NICE makes first immunotherapy combination immediately available in advanced kidney cancer"